Omicron variant spreads around the world
Medicago – a company that has used a close relative of the tobacco plant to make vaccines – said a phase 3 trial of its Covid-19 vaccine has shown it to be 75% effective against symptoms of any severity caused by the Delta variant of the virus.
The company said no serious adverse events were seen in its trial involving 24,000 volunteers in Canada, the United States, the United Kingdom, Mexico, Argentina and Brazil.
He said he would seek regulatory approval from Canadian authorities and initiate the US and EU clearance processes.
The company said the vaccine’s overall efficacy rate against all variants of the virus was 71%, adding:
âThe vaccine candidate has demonstrated 75.3% efficacy against COVID-19 of any severity for the globally dominant Delta variant. The efficacy was 88.6% against the Gamma variant. “
Reactions to the vaccine were generally mild and transient, the company said. He said he would publish the results in a peer-reviewed journal.
The company uses a close relative of the tobacco plant, called Nicotiana benthamiana, to produce so-called viral-like particles. They are non-infectious facsimiles of the virus, designed to prepare the immune system to recognize a real virus if it infects someone.
The vaccine uses an adjuvant – an immune system booster – made by GlaxoSmithKline.
“If approved, we will contribute to the global fight against the COVID-19 pandemic with the world’s first herbal vaccine for use in humans,” said Takashi Nagao, CEO and President of Medicago, in a statement. Mitsubishi Tanabe Pharma Corporation is the parent company of Medicago.